Omic biomarkers and genetic panels: key tools for patient stratification and predicting response to therapy in prostate cancer

Omic biomarkers and genetic panels: key tools for patient stratification and predicting response to therapy in prostate cancer

Karen P. Sarango-González 1, 2 , Natalia C. Bailón-Moscoso 2

1 Análisis diagnóstico y biológico de laboratorio, Universidad Técnica Particular de Loja, Loja, Ecuador; 2 Departamento de Ciencias de la Salud, Universidad Técnica Particular de Loja, Loja, Ecuador

*Correspondence: Karen P. Sarango-González. Email: kpsarango1@utpl.edu.ec

Abstract

Prostate cancer (PCa) is the second most diagnosed cancer in men, with a high incidence and mortality worldwide. Advanced genomic characterization using OMICs technologies, such as next-generation sequencing, allows a deeper understanding of the genetic and epigenetic alterations associated with PCa, facilitating accurate diagnoses, patient classification, and prediction of therapeutic response. This article analyzes advances in the use of OMICs to identify molecular biomarkers and genetic panels that allow personalized treatments, reduce invasive interventions, and improve disease prognosis, highlighting the importance of precision medicine in current oncology care.

Keywords: Prostate cancer. Next-generation sequencing. Genetic panels.

Contents

This content is only available in Spanish.
DOI not available
Add to Mendeley

This content is only available in Spanish.

    PERMANYER

    Mallorca, 310
    08037 Barcelona (España)

    Arquímedes, 190 – Colonia Polanco
    Delegación Miguel Hidalgo
    11560 Ciudad de México (México)

    RECURRING LINKS
    CLOCKSS is a dak archive that ensures the long-term survival of web-based scholary publications, governed by and for its stakeholders.

    This journal adheres to the principles established by the Committee on Publication Ethics

    English versión
    DOI not available

    Editorial times

    The editorial process consists of 6 stages:

    1. Reception of the manuscript (indeterminate, depending on whether the author meets the requirements): its objective is to verify that the manuscript complies with the specifications of these instructions for authors and that the submitted documentation is complete.

    2. Initial editorial review (maximum 5 business days): its objective is to corroborate the relevance, timeliness, originality, and scientific contribution of the manuscript, as well as the methodological and statistical soundness of the study. At this time, it will be submitted to an electronic plagiarism detection system. Derived from this, a rejected opinion may be obtained, or it will be sent for review by peer researchers.

    3. Review by peer researchers (maximum 30 business days): the opinion of at least two experts in the area in question will be obtained, who will evaluate the technical and methodological aspects of the investigation.

    4. Editorial review (maximum 7 business days): its objective is to make a decision based on the opinion of peer reviewers. The opinion can be rejected, major changes, minor changes or accepted. In the case of major or minor changes, it will be submitted again for evaluation by the initial peer reviewers.

    5. Final edition (6 weeks): its objective is the technical and linguistic edition (and translation), layout of galleys, DOI assignment, and correction by the author.

    6. Advanced publication: All manuscripts will be published ahead of print on the journal’s website as soon as they complete the editing process, until they are incorporated into a final issue of the journal.